<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03" generated-datetime="2026-05-12T13:25:17+00:00"><iati-activity last-updated-datetime="2026-05-12T13:25:14+00:00" xml:lang="en">
  <iati-identifier>KE-KRA-P051637065Q-VacAMR-NIHR156011</iati-identifier>
  <reporting-org type="21" ref="KE-KRA-P051637065Q" secondary-reporter="0">
    <narrative xml:lang="en">Health Research Operations Kenya Limited</narrative>
  </reporting-org>
  <title>
    <narrative xml:lang="en">NIHR Global Health Research Group on Vaccines to Control Respiratory Pathogens and AMR across Africa (VacAMR)</narrative>
  </title>
  <description type="1">
    <narrative xml:lang="en">AMR-attributable deaths (~1.3 million/yr) are mostly due to respiratory infection (LRI). Annually there are &gt;2 million lower respiratory infection (LRI) deaths globally, most commonly in sub- Saharan Africa (SSA).&#13;
Streptococcus pneumoniae (Spn), then RSV &amp; Hib are the leading causes of LRI deaths among under-5 children. AMR Klebsiella pneumoniae is a leading cause of pneumonia &amp; sepsis in newborns &amp; vulnerable adults.&#13;
Influenza virus, RSV &amp; Spn infections are major drivers of antimicrobial use &amp; therefore AMR. Deaths due to AMR respiratory pathogens are vaccine preventable. We therefore propose to improve AMR control by focusing on preventing disease syndromes (e.g. fever &amp; pneumonia), as part of a multimodal approach that includes vaccine and non-vaccine interventions. Building on previous NIHR-funded success, we will tackle AMR through new strategic South-South partnerships between KEMRI-Wellcome, Kenya, Malawi-Liverpool-Wellcome (Kamuzu University of Health Sciences), Navrongo Health Research Centre, Ghana Nigeria Centre for Disease Control, &amp; Nigerian Institute of Medical Research Overall Aim: Africa-led transformation of the public health approach to controlling respiratory pathogens &amp; AMR through vaccine &amp; non-vaccine-based multimodal interventions.</narrative>
  </description>
  <description type="2">
    <narrative xml:lang="en">Identify multimodal interventions to reduce AMR, developing the evidence base, co-creating interventions, modelling impact &amp; prioritising methodologies. ii) Accelerate implementation of diagnostic approaches to support AMR intervention evaluation. iii) Evaluate candidate immune markers of protection to support intervention &amp; outcome evaluation. iv) Strengthen evidence-to-policy translation. v) Engage communities to evaluate AMR risk &amp; identify behaviour change interventions. vi) Empower Africa-based leadership &amp; innovation in AMR.</narrative>
  </description>
  <participating-org role="2">
    <narrative xml:lang="en">University College London</narrative>
  </participating-org>
  <participating-org role="4">
    <narrative xml:lang="en">London School of Hygiene and Tropical Medicine</narrative>
  </participating-org>
  <participating-org role="4">
    <narrative xml:lang="en">Liverpool School of Tropical Medicine</narrative>
  </participating-org>
  <participating-org role="4">
    <narrative xml:lang="en">Malawi-Liverpool Wellcome Programme</narrative>
  </participating-org>
  <participating-org role="4">
    <narrative xml:lang="en">Navrongo Health Research Centre</narrative>
  </participating-org>
  <participating-org role="4">
    <narrative xml:lang="en">Nigeria Centre for Disease Control</narrative>
  </participating-org>
  <participating-org role="4">
    <narrative xml:lang="en">Centre Suisse de Recherches Scientifiques en Côte d'Ivoire</narrative>
  </participating-org>
  <participating-org role="4">
    <narrative xml:lang="en">Nigeria Institute of Medical Research</narrative>
  </participating-org>
  <participating-org role="4">
    <narrative xml:lang="en">Wellcome Connecting Science</narrative>
  </participating-org>
  <participating-org role="4">
    <narrative xml:lang="en">Kamuzu College of Health Sciences</narrative>
  </participating-org>
  <activity-status code="2"/>
  <activity-date type="2" iso-date="2024-07-01"/>
  <recipient-country code="KE" percentage="25">
    <narrative xml:lang="en">Collaborating organisation</narrative>
  </recipient-country>
  <recipient-region code="298" percentage="44.1" vocabulary="1"/>
  <recipient-region code="89" percentage="30.9" vocabulary="1"/>
  <sector code="12182" percentage="100" vocabulary="1"/>
  <default-flow-type code="10"/>
  <default-finance-type code="110"/>
  <default-aid-type code="B03" vocabulary="1"/>
  <default-tied-status code="5"/>
  <budget type="1" status="2">
    <period-start iso-date="2024-07-01"/>
    <period-end iso-date="2025-06-30"/>
    <value currency="GBP" value-date="2024-07-01">3026376</value>
  </budget>
  <transaction humanitarian="1">
    <transaction-type code="1"/>
    <transaction-date iso-date="2024-07-01"/>
    <value currency="GBP" value-date="2024-07-01">760307.69</value>
  </transaction>
</iati-activity></iati-activities>
